[ not posted in response to any given individual ]
Hey, guys and gals, we're getting a little chatty here. This thread has traditionally had a high meat:noise ratio. Let's keep it that way, with a focus on sector strengths and weaknesses.
Moreover, it's not allowed to talk about the "sector" when striking at valuation issues. A CRGN is very different from a VRTX. No easy generalizations allowed.
Michael.... your earlier response indicates that you don't know the thread..... it's not a "rah, rah, go biotech" thread. I extended a polite invitation for you to settle in and be comfortable, not to become a cheerleader.
Switching subjects, just made this post to the valuation thread.....
Message 12924033
In the following thread, I said......
it's the most out-of-whack stocks in the sector that traditionally determine when the sector as a whole comes back.
Comments are sought.
Switching subjects again..... we closed the "T/FIF" thread after having accomplished an agenda..... we showed that, in a sector given up for dead, stock-pickers could humble those fund managers that were blaming biotech for their poor performance. We conclusively showed, with portfolios to back it up, that the best biotech analysis available, anywhere at any price, is here at SI for free.
All references to "portfolios" of course include the VDXX portfolio, the grandaddy of SI biotech tracking efforts.
Having successfully commanded a new attitude among sector fund managers, we then opened the "son of T/FIF" thread. We rode the rally, with documentation, as nobody else can claim to have ridden it.
We now enter a new era, with valuations that are a full order of magnitude (!) greater than those achieved during other liquidity windows. We are again at a point where money can be made, using prudence, short. We are again at the point where a fund manager, having under-performed, is bad-mouthing the "sector". Jerk.
So..... what to call the new thread, where I'll begin a focus on proteomics? The new thread will have a "what now?" theme.
Son of T/FIF, the Sequel? |
